People | December 06, 2022
Biocon Biologics elevates Shreehas Tambe as MD & CEO
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Subscribe To Our Newsletter & Stay Updated
